Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Endo-peptidases are enzymes that cleave peptide bonds within proteins, and certain types—particularly asparaginase (an endopeptidase)—have a validated role in the treatment of leukemia, especially acute lymphoblastic leukemia (ALL). Asparaginase works by depleting the amino acid asparagine, which leukemic cells are unable to synthesize sufficiently on their own. Normal cells can produce asparagine, but leukemic lymphoblasts depend on circulating asparagine for survival and proliferation. By administering asparaginase, asparagine is broken down, effectively starving the leukemic cells and leading to their apoptosis.

This mechanism is well-established and forms a standard part of multi-agent chemotherapy protocols for pediatric and some adult ALL cases. Multiple randomized controlled trials and meta-analyses confirm that asparaginase improves remission rates and overall survival in these patients. However, it is important to note that not all endo-peptidases have demonstrated efficacy; the evidence is specific to asparaginase and its analogues. Other endo-peptidases are not used for leukemia treatment and lack clinical validation in this context.

In conclusion, the use of asparaginase (a specific type of endo-peptidase) in leukemia is strongly supported by scientific evidence, though the rating is not maximal (2/5) because this applies only to a narrow subclass of endo-peptidases and a specific leukemia subtype. Broader claims about endo-peptidases in general are not substantiated.

More about endo-peptidase
More about Leukemia

Other ingredients used for Leukemia

Other health conditions supported by endo-peptidase

Products containing endo-peptidase